• Korean Journal of Psychosomatic Medicine
• /
• v.22 no.2
• /
• pp.63-70
• /
• 2014

The prevalence of obesity and overweight is increasing in mood disorder, and it is connected to an increased cardiovascular mortality. Because of them, treatment for obesity may be an essential part of mood disorder treatment. Similar to the general population, non-pharmacological treatment such as correction of life habits should be considered first of all. If this approaches are fail, pharmacological treatment for obesity would be required as next step. Any drug for obesity is not approved officially in mood disorder. So approved drugs in general population, and drugs supported by several studies are prescribed in clinical settings. Several treatment guidelines for mood disorder and studies support that orlistat, metformin, topiramate and bupropion is effective and safe.

• The Journal of the Korea Contents Association
• /
• v.17 no.6
• /
• pp.540-550
• /
• 2017

To investigate a variety of nonpharmacologic interventions have confirmed what the symptoms and effects, mainly interventions by acting on behavioral and psychological symptoms of dementia was conducted a meta-analysis. Data were collected from online search engines using search words from domestic and foreign article database. The researcher independently and among the pre-post experimental studies published from January 2000 to June 2016, recalled applying for the elderly with dementia presents the effect of treatment group and the control group RCT in this study were included in the study. The results of this meta-analysis showed that, effect size of the nonpharmacologic interventions of total -0.33, occupational therapy - 0.26, multi-sensory stimulation intervention -0.65 was significant beneficial effects to elderly with dementia(p<.05). According to interventions as a major affected the symptoms associated with behavioral problems, mainly aggression, memory-related problem behavior in the home-based program. Also, reminiscence therapy and occupational therapy is generally apathy, multi-sensory stimulation and music therapy was confirmed that there was a major change in behavior anxiety or agitation. The results of this study confirmed that various nonpharmacologic interventions were effective on behavioral psychological symptoms of dementia patients and confirmed the main symptoms of intervention.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1993.04a
• /
• pp.104-104
• /
• 1993

시방성 제제에 대한 연구는 주로 제제학적 수단에 의한 약효의 지속화로서 제제설계상 제형개발 및 투여제형에서의 약물방출 조절로 체내의 유효 혈중농도를 유지한다. 이에 약물 방출 조절용 물질의 하나로서 체내 분해가 가능하고 독성이 없는 생체 고분자인 Chitosan이 약물방출 담체로서 양호함에 착안하여 약물의 서방화를 기하고자 본 실험에 착수 하였다. 모델 약물로서는 sulfamethoxazole, acetaminophen, sylimarin을 사용하여 chitosan gel 과 혼합비를 달리하여 고형 문산체를 조제하고 이것을 formaldehyde, glutaraldehyde, 1acetaldehyde, butylaldehyde 4종의 aldehyde를 사용하여 농도에 따른 가교화가 in vitro에서의 약물용출에 미치는 영향을 검토하였으며, 또한 위장을 거쳐 소화효소 또는 장내미생물 효소에 의한 chitosan 분해로 약물 방출의 촉진을 실험한바 지견을 얻었기에 보고한다.

• The Journal of the Convergence on Culture Technology
• /
• v.8 no.5
• /
• pp.71-80
• /
• 2022

The purpose of this study was to evaluate the effects of the non-pharmacological intervention on depressive symptoms in the older adults with mild cognitive impairment. A total of 1,147 studies were retrieved from PubMed, CINAHL, PsycINFO, Science direct, KISS, RISS, and DBPia. Twenty-one studies which met the criteria were selected and the quality assessment was conducted independently by two investigators. The effect size of non-pharmacological intervention was estimated using Comprehensive Meta-Analysis 3.0. The overall effect size turned out to be the medium effect size (Hedges' g=-0.68, 95% CI=-1.01~-0.36). As a result of the subgroup analysis, the intervention type was statistically significant. The effect size of cognitive intervention (Hedges' g=-1.03, 95% CI=-1.43~-0.61) and multi component intervention (Hedges' g=-0.97, 95% CI=-1.63~-0.33) was greater than excise intervention (Hedges' g=-0.53, 95% CI=-1.16~0.03). This study shows that non-pharmacological intervention was also effective in reducing depressive symptoms in the older adults with mild cognitive impairment. Based on the research results, it is expected that various non-pharmacological intervention studies will be attempted to improve cognitive function and depressive symptoms of the older adults with mild cognitive impairment.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1993.04a
• /
• pp.87-87
• /
• 1993

항 Histamine쟤의 효과적인 응용과 그 개발율 위한 자료를 얻고자 이들 약물의 H$_1$-receptor와 muscarinic receptor에 대한 작용의 상대적 역가를 비교하였다. 본 실험에 이용된 기니픽 회장에는 [$^3$H]QHB어 대한 단일 muscarinic receptor가 존재하였으며 [$^3$H]QNB의 affinity와 결합부위농도는 각각 54 pM 및 156 fmol/mg이었다. 항 histamine제는 muscarinic receptor에 대한 [$^3$H]QNB결합을 억제하였으며 [$^3$H]QNB 결합억제로부터 추정된 항 histamine제의 Ki치가 0.008$\mu$M-1.6$\mu$M로서 항 histamine제의 종류에 따라 현저한 차이가 있었고, 이 결과는 carbachol 반응억제로부터 추정된 각 항 histamine제의 muscarinic receptor에 대한 affinity(K$_{M}$)와 유사하였다. 한편 histamine수축반응 억제로부터 추정된 항 histamine재의 H$_1$-receptor에 대한 affinity(K$_{H}$ ) 역시 0.15nM-56.5nM로서 약물에 따라 차이가 있었고 각 약물의 $K_{M}$ /K$_{H}$ 비가 3-2300으로 H$_1$-receptor에 대한 역가와 muscarinic receptor에 대한 역가 사이에는 상관성이 없었다. 즉 유사한 항 allergy 작용을 일으킬 수 있는 치료혈중농도에서도 muscarinic receptor 차단작용이 다르며 본 실험에 사용한 13종의 기존 항 histamine제중 triprolidine이 $K_{M}$ /K$_{H}$ 비가 가장 높았고 diphenidol이 가장 낮았다. 이상의 결과로 보아 항 histamine제의 muscarinic receptor 차단작용은 이들 약물의 항 alleragy 효과에 필요한 작용이 아니며 본 실험에서 추정된 항 histamine제의 H$_1$-receptor와 muscarinic receptor에 대한 상대적 역가는 이들 약물의 선택과 평가에 중요한 지표가 될수 있을 것으로 생각된다.

• Korean Journal of Biological Psychiatry
• /
• v.1 no.1
• /
• pp.117-123
• /
• 1994

This study was performed to examine the role of neuroleptics may in the development of neurologic soft signs in patients with schizophrenia. Neurologic soft signs were evaluated in 28 neuroleptic naive patients with schizophrenia or schizophreniform disorder and 31 neuroleptic non-naive patients with schizophrenia using a structured tool for measuring neurologic abnormalities, Neurological Evaluation Scale-Korean version(NES-K). Relationship to dose, duration and neurological side effects of neuroleptic treatment were also evaluated. Total scores of NES-K in neuroleptic naive group were significantly higher than those of non-naive group. Scores of motor coordination, sequencing of complex motor acts and others items in functional subcategories were also significantly higher in drug-naive patients. The sensory integration item was not different between two groups. After controlling covariates such ac dose of neuroleptics, age and sex, total scores, motor coordination and others items of NES-K were significantly higher in neuroleptic naive group. However there was no difference between drug naive and non-naive group in the sequencing of complex motor acts item due to effects of these covariates. In neuroleptic non-naive group the dosage of neuroleptics correlated with the motor coordination item, nor were there relationships between duration and side effects of neuroleptic treatment and neurologic soft signs. These findings suggest that neuroleptic treatment may play a only relative role in the development of neurologic soft signs in patients with schizophrenia and these abnormalities may be one of possible trait markers of schizophrenia. To elucidate this opinion, well-controlled, prospective study in same subjects will be helpful.

• Journal of Science and Technology Studies
• /
• v.14 no.1
• /
• pp.87-116
• /
• 2014

This article focuses on synthetic hormone consumption that illegal act of heterogeneous forms of pharmaceuticalization. Athletes are not unfamiliar with the use of synthetic hormones that contain anabolic steroids. Synthetic hormones are used to increase muscle mass and strength. This drug use practice cannot simply be viewed as illegal. Athletes accumulate knowledge on these hormones that conflicts with the knowledge proffered by physicians and they consume drugs responsibly. Physicians' knowledge of these hormones is limited to their use in the treatment of abnormalities. Athletes, however, are expanding the role of these hormones to include their potential for enhancement. Thereby, a new value is assigned to synthetic hormones, and an informal market is formed. Previous studies in the fields of biopolitics and biomedicalization have mainly focused on the formal connection between biomedical science and the institutional network. This article, therefore, analyzes the informal and the various aspects of biomedicalization.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1994.04a
• /
• pp.196-196
• /
• 1994

DDS에 활용될 수 있는 고분자 소재를 개발할 목적으로 물성 및 응용성이 우수한 고분자 겔에 관한 연구를 수행하였다. Ethylene oxide,propylene oxide 각각의 copolymer인 poloxamer등의 prepolymer들을 triisocyanate로 가교시키고 diisocyanate 로 chain이 연장된 "soft hydrogel"을 제조하였다. 모델 약물을 선정하여 crosslinker와 extender의 조절에 따른 hydrogel의 약물 방출 조절능을 조사하였으며 그 기전을 규명하고자 하였다. 가교부위에 urethane bond를 함유한 soft hydtogel은 건조상태에서도 고무와 같은 전연성을 보여 일반적인 hydrogel과 대비되는 특성을 보였으며 이에 따른 다양한 활용성이 기대되었다. Extender및 crosslinker의 비율에 따라서 이 rubber elasticity가 조절되었다. 가교도가 감소할수록 팽윤도가 상승하였고 이에 따른 약물방출도 증가함을 확인하였다. 또한 Prepolymer의 분자량 및 친수/소수성등의 물성에 따라 약물방출을 조절할 수 있었다. 제조된 hydrogel에 조절방출시 필요한 기능을 부가시키고자 poly(carylic acid)류와 IPN 공중합체를 합성하여 물성을 조사하였고 비이온성/양이온성/음이온성 모델약물을 선정하여 pH에 따른 가변적 팽윤도와 이온성 상호작용등에 근거한 약물 조절방출기전을 조사하였다.기전을 조사하였다.

• Environmental Analysis Health and Toxicology
• /
• v.23 no.3
• /
• pp.165-170
• /
• 2008

간의 약물대사는 흡수된 외인성물질의 배설을 위한 중추적인 역할을 수행하면 이 반응은 일상대사와 이상대사효소로 구성된 약물대사효소계에 의해 매개된다. 약물대사효소의 발현과 활성은 외인성물질의 노출에 의해 유도되거나 억제되며 이 결과는 약물상호작용을 발생시키는 주요한 원인이다. 또한 당뇨, 비만, 영양실조, 음주, 염증반응 등의 병적인 생리상태는 간에서 약물대사효소의 발현과 활성을 조절하는 것으로 보고되고 있다. 이러한 변동은 치료약물 또는 환경오염물질에 대한 인체의 반응성에 영향을 미치며 결과적으로 예측하지 못한 부작용이나 독성을 발생시킬 수 있다. 본 논문에서는 당뇨병에서 약물대사효소의 발현변화를 정리하였다.

• Polymer(Korea)
• /
• v.36 no.4
• /
• pp.500-506
• /
• 2012

In this study, we developed and optimized hydrophilic polymer based solid dispersion formulations (SDs) for enhancing the aqueous solubility of eprosartan, one of poorly soluble drugs, that has been broadly used for the treatment of high blood pressure. Poly(ethylene glycol) (PEG) and poly(vinyl pyrrolidone) (PVP) based SDs were prepared by hot melting and solvent evaporation methods and the drug/polymer composition varied in the range of 1:1~1:5 with or without poloxamer 407 (P407) as a polymeric surfactant. The SDs prepared by solvent evaporation showed more reduced crystallinity than ones by hot melting, and PVP based SDs showed more enhanced solubility and lower crystallinity than PEG based SDs. Furthermore, it was observed from DSC and PXRD analysis that the SDs with P407 (drug:polymer: P407 = 1:5:1) demonstrated no crystallinity and the most enhanced solubility (more than 3~4 times).